Aligned Genetics Inc (238120) - Net Assets
Based on the latest financial reports, Aligned Genetics Inc (238120) has net assets worth ₩35.50 Billion KRW (≈ $24.05 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩45.11 Billion ≈ $30.57 Million USD) and total liabilities (₩9.61 Billion ≈ $6.51 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore balance sheet size of Aligned Genetics Inc for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩35.50 Billion |
| % of Total Assets | 78.69% |
| Annual Growth Rate | 21.69% |
| 5-Year Change | 65.37% |
| 10-Year Change | N/A |
| Growth Volatility | 92.73 |
Aligned Genetics Inc - Net Assets Trend (2015–2024)
This chart illustrates how Aligned Genetics Inc's net assets have evolved over time, based on quarterly financial data. Check Aligned Genetics Inc (238120) tangible net worth to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Aligned Genetics Inc (2015–2024)
The table below shows the annual net assets of Aligned Genetics Inc from 2015 to 2024. For live valuation and market cap data, see market value of Aligned Genetics Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩35.49 Billion ≈ $24.05 Million |
+13.36% |
| 2023-12-31 | ₩31.31 Billion ≈ $21.22 Million |
+8.53% |
| 2022-12-31 | ₩28.85 Billion ≈ $19.55 Million |
+6.88% |
| 2021-12-31 | ₩26.99 Billion ≈ $18.29 Million |
+25.76% |
| 2020-12-31 | ₩21.46 Billion ≈ $14.55 Million |
+2.37% |
| 2019-12-31 | ₩20.97 Billion ≈ $14.21 Million |
+0.38% |
| 2018-12-31 | ₩20.89 Billion ≈ $14.16 Million |
-7.74% |
| 2017-12-31 | ₩22.64 Billion ≈ $15.34 Million |
-6.38% |
| 2016-12-31 | ₩24.18 Billion ≈ $16.39 Million |
+298.87% |
| 2015-12-31 | ₩6.06 Billion ≈ $4.11 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Aligned Genetics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 943631107000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩5.85 Billion | 16.48% |
| Common Stock | ₩7.19 Billion | 20.26% |
| Other Components | ₩22.45 Billion | 63.26% |
| Total Equity | ₩35.49 Billion | 100.00% |
Aligned Genetics Inc Competitors by Market Cap
The table below lists competitors of Aligned Genetics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tigers Realm Coal Ltd
AU:TIG
|
$27.74 Million |
|
Audacia SAS
PA:ALAUD
|
$27.75 Million |
|
Garden Stage Limited Ordinary Shares
NASDAQ:GSIW
|
$27.75 Million |
|
TOP Ships Inc.
NASDAQ:TOPS
|
$27.76 Million |
|
U-Tech Co Ltd
KQ:178780
|
$27.72 Million |
|
Steel Hawk Berhad
KLSE:0320
|
$27.71 Million |
|
KC Feed Co. Ltd
KQ:025880
|
$27.70 Million |
|
Harvard Bioscience Inc
NASDAQ:HBIO
|
$27.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aligned Genetics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 31,311,482,650 to 35,494,356,130, a change of 4,182,873,480 (13.4%).
- Net income of 4,128,033,780 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩4.13 Billion | +11.63% |
| Other Changes | ₩54.84 Million | +0.15% |
| Total Change | ₩- | 13.36% |
Book Value vs Market Value Analysis
This analysis compares Aligned Genetics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.18x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.86x to 1.18x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩3394.79 | ₩2910.00 | x |
| 2017-12-31 | ₩3149.09 | ₩2910.00 | x |
| 2018-12-31 | ₩2905.38 | ₩2910.00 | x |
| 2019-12-31 | ₩2916.29 | ₩2910.00 | x |
| 2020-12-31 | ₩2985.43 | ₩2910.00 | x |
| 2021-12-31 | ₩1877.21 | ₩2910.00 | x |
| 2022-12-31 | ₩2006.39 | ₩2910.00 | x |
| 2023-12-31 | ₩2177.60 | ₩2910.00 | x |
| 2024-12-31 | ₩2468.50 | ₩2910.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aligned Genetics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.63%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 26.16%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 1.25x
- Recent ROE (11.63%) is above the historical average (2.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -4.31% | -6.38% | 0.60x | 1.13x | ₩-867.64 Million |
| 2016 | -6.43% | -33.02% | 0.18x | 1.07x | ₩-3.97 Billion |
| 2017 | -7.75% | -31.13% | 0.23x | 1.07x | ₩-4.02 Billion |
| 2018 | -7.60% | -27.98% | 0.25x | 1.10x | ₩-3.68 Billion |
| 2019 | 0.56% | 1.50% | 0.32x | 1.17x | ₩-1.98 Billion |
| 2020 | 2.18% | 5.88% | 0.31x | 1.19x | ₩-1.68 Billion |
| 2021 | 20.53% | 47.12% | 0.34x | 1.28x | ₩2.84 Billion |
| 2022 | 8.09% | 16.96% | 0.37x | 1.28x | ₩-552.22 Million |
| 2023 | 10.33% | 21.27% | 0.37x | 1.31x | ₩104.87 Million |
| 2024 | 11.63% | 26.16% | 0.36x | 1.25x | ₩578.60 Million |
Industry Comparison
This section compares Aligned Genetics Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $120,744,551,957
- Average return on equity (ROE) among peers: 5.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aligned Genetics Inc (238120) | ₩35.50 Billion | -4.31% | 0.27x | $27.72 Million |
| Shinhung (004080) | $113.89 Billion | 8.10% | 0.23x | $89.01 Million |
| HansBiomed Corporation (042520) | $39.39 Billion | 8.88% | 0.13x | $164.76 Million |
| JVM Co. Ltd (054950) | $123.61 Billion | 4.69% | 0.46x | $183.43 Million |
| U&I Corporation (056090) | $62.85 Billion | -1.29% | 0.23x | $65.92 Million |
| Huvitz Co. Ltd (065510) | $68.86 Billion | 9.49% | 0.66x | $51.23 Million |
| Vieworks Co. Ltd (100120) | $215.64 Billion | 6.82% | 0.36x | $147.13 Million |
| Corentec Co Ltd (104540) | $86.12 Billion | 4.71% | 1.17x | $33.36 Million |
| Hironic Co. Ltd (149980) | $58.67 Billion | 5.00% | 0.15x | $50.01 Million |
| Humasis Co. Ltd (205470) | $287.33 Billion | -19.29% | 0.21x | $164.10 Million |
| NH SPAC 2 (206640) | $151.09 Billion | 29.36% | 0.27x | $163.47 Million |
About Aligned Genetics Inc
Aligned Genetics, Inc. offers cellular imaging and biomolecular analysis solutions worldwide. It also provides molecular diagnostic solutions for rapid results under the Genescale name; and advanced imaging and analysis solutions under the Logos Biosystems name. The company was formerly known as Logos Biosystems, Inc. and changed its name to Aligned Genetics, Inc. in September 2020. Aligned Genet… Read more